Konen, J.M.; Rodriguez, B.L.; Fradette, J.J.; Gibson, L.; Davis, D.; Minelli, R.; Peoples, M.D.; Kovacs, J.; Carugo, A.; Bristow, C.;
et al. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers 2019, 11, 462.
https://doi.org/10.3390/cancers11040462
AMA Style
Konen JM, Rodriguez BL, Fradette JJ, Gibson L, Davis D, Minelli R, Peoples MD, Kovacs J, Carugo A, Bristow C,
et al. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers. 2019; 11(4):462.
https://doi.org/10.3390/cancers11040462
Chicago/Turabian Style
Konen, Jessica M., B. Leticia Rodriguez, Jared J. Fradette, Laura Gibson, Denali Davis, Rosalba Minelli, Michael D. Peoples, Jeffrey Kovacs, Alessandro Carugo, Christopher Bristow,
and et al. 2019. "Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer" Cancers 11, no. 4: 462.
https://doi.org/10.3390/cancers11040462
APA Style
Konen, J. M., Rodriguez, B. L., Fradette, J. J., Gibson, L., Davis, D., Minelli, R., Peoples, M. D., Kovacs, J., Carugo, A., Bristow, C., Heffernan, T., & Gibbons, D. L.
(2019). Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers, 11(4), 462.
https://doi.org/10.3390/cancers11040462